Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Current Assets (2016 - 2025)

Haemonetics has reported Current Assets over the past 16 years, most recently at $943.7 million for Q4 2025.

  • Quarterly results put Current Assets at $943.7 million for Q4 2025, down 6.18% from a year ago — trailing twelve months through Dec 2025 was $943.7 million (down 6.18% YoY), and the annual figure for FY2025 was $935.0 million, up 21.6%.
  • Current Assets for Q4 2025 was $943.7 million at Haemonetics, up from $899.7 million in the prior quarter.
  • Over the last five years, Current Assets for HAE hit a ceiling of $1.0 billion in Q4 2024 and a floor of $684.4 million in Q3 2021.
  • Median Current Assets over the past 5 years was $769.3 million (2023), compared with a mean of $813.8 million.
  • Biggest five-year swings in Current Assets: decreased 9.88% in 2021 and later surged 31.49% in 2024.
  • Haemonetics' Current Assets stood at $699.2 million in 2021, then rose by 1.01% to $706.3 million in 2022, then grew by 8.31% to $765.0 million in 2023, then skyrocketed by 31.49% to $1.0 billion in 2024, then decreased by 6.18% to $943.7 million in 2025.
  • The last three reported values for Current Assets were $943.7 million (Q4 2025), $899.7 million (Q3 2025), and $913.2 million (Q2 2025) per Business Quant data.